Literature DB >> 21449949

Current therapeutic strategies in non-alcoholic fatty liver disease.

J K Dowman1, M J Armstrong, J W Tomlinson, P N Newsome.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from simple steatosis through steatohepatitis (NASH) to increasing fibrosis and eventual cirrhosis. NAFLD is the hepatic manifestation of the metabolic syndrome and has now become the most common cause of liver disease in Western countries, with the more advanced stages of disease being associated with an increased risk of liver-related morbidity and mortality. The optimal management of patients with NAFLD remains a clinical challenge. The aim of this study is to describe established and emerging strategies for the treatment of NAFLD. Relevant research and review articles were identified by searching PubMed. Selected articles referenced in these publications were also examined. Good quality randomized controlled studies have demonstrated the need for multifaceted lifestyle interventions in patients with NAFLD including the need for diet, exercise and behavioural counselling. Despite several trials of pharmacological agents, no highly effective treatment yet exists, with surgery representing the mainstay for advanced disease. A multidisciplinary approach, with a major focus on lifestyle change, represents best treatment pending the development of new therapeutic options.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21449949     DOI: 10.1111/j.1463-1326.2011.01403.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  33 in total

1.  Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

Authors:  Miroslaw Kornek; Michael Lynch; Shruti H Mehta; Michelle Lai; Mark Exley; Nezam H Afdhal; Detlef Schuppan
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 2.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 3.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

4.  New Role of Hispidulin in Lipid Metabolism: PPARα Activator.

Authors:  Xinchi Wu; Juan Xu
Journal:  Lipids       Date:  2016-10-15       Impact factor: 1.880

5.  GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.

Authors:  Xiao-Min Xin; Mu-Xiao Zhong; Gong-Li Yang; Yao Peng; Ya-Li Zhang; Wei Zhu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

6.  TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.

Authors:  Li Li; Jing Chen; Yinxing Ni; Xiaoli Feng; Zhigang Zhao; Peijian Wang; Jing Sun; Hao Yu; Zhencheng Yan; Daoyan Liu; Bernd Nilius; Zhiming Zhu
Journal:  Pflugers Arch       Date:  2012-03-07       Impact factor: 3.657

7.  Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience.

Authors:  Jeremy F L Cobbold; Sarrah Raveendran; Christopher M Peake; Quentin M Anstee; Michael S Yee; Mark R Thursz
Journal:  Frontline Gastroenterol       Date:  2013-05-23

Review 8.  Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Ciarán P Fisher; Andrzej M Kierzek; Nick J Plant; J Bernadette Moore
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

9.  Role of β-adrenergic receptors in regulation of hepatic fat accumulation during aging.

Authors:  Paramita M Ghosh; Zhen-Ju Shu; Bing Zhu; Zhongding Lu; Yuji Ikeno; Jeffrey L Barnes; Chih-Ko Yeh; Bin-Xian Zhang; Michael S Katz; Amrita Kamat
Journal:  J Endocrinol       Date:  2012-03-28       Impact factor: 4.286

Review 10.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.